FDA approves Topamax for migraine prevention in adolescents The U.S. FDA approved Topamax for prevention of migraine headaches in adolescents ages 12 to 17. This is the first FDA approval of a drug for migraine prevention in this age group. The medication is taken on a daily basis to reduce the frequency of migraine headaches. Topamax was first approved by the FDA in 1996 to prevent seizures. It was approved for migraine prevention in adults in 2004. Topamax must be dispensed with a Medication Guide that describes important safety information about the drug. Topamax is manufactured by Janssen Pharmaceuticals.
Leerink medical devices analyst holds an analyst/industry conference call Medical Device Analyst Newitter, along with MEDACorp Specialists Dorance Dillon and Terence Farrell, discuss the Centers for Medicare & Medicaid Services' recently proposed "Comprehensive Care For Joint Replacement Payment Model" and how this model might influence ortho pricing and hospital-vendor relationships on an Analyst/Industry conference call to be held on August 24 at 1 pm.